Methods: Patients with PD in stable phase (n=17) were randomly assigned to each group, ESWT n=9 or placebo n=8. All patients were treated once a week for 5 consecutive weeks. At baseline an ultrasound was conducted to examine whether the plaque was calcified. All patients received similar instructions on how to utilize the vacuum pump followed by manipulation exercises. Patients submitted pictures at baseline to assess penile curvature and filled out questionnaires; Peyronies Disease Questionnaire (PDQ) and International Index of Erectile Function-5 (IIEF-5).

Results: Seventeen patients were included, and no dropouts. Mean change in penile curvature was -17.56 degrees in the active group, and -7.88 in the placebo (p=0.066). Mean IIEF-5 increased by 1 in the active group and decreased by 0.4 in the placebo group (p=0.36). PDQ pain score decreased by 2.1 in the active group, and increased by 0.1 in the placebo group (p=0.072).

Conclusion: These preliminary results suggest that LI-ESWT and vacuum pump combined with manipulation exercises may represent a viable non invasive treatment for men diagnosed with PD. The trial is on-going in order to see whether there is potential of combining LI-ESWT with a vacuum pump followed by manipulation exercises.

Policy of full disclosure: None

HP-09-007

THE USE OF A PENILE TRACTION DEVICE REDUCES THE NEED OF CYCLES OF COLLAGENASE IN PATIENTS WITH PEYRONIE’S DISEASE

García-Gómez, B.1; Romero-Otero, J.2; Alonso-Isa, M.3; Medina-Polo, J.2; García-Rojo, E.2; González-Padilla, D.2; Rodríguez-Antolín, A.2

12 de Octubre University, Hospital, Urology, Spain; 2Hospital 12 de Octubre, Madrid, Spain

Objective: To present our experience and results with the use of collagenase of the Clostridium Histolyticum (Xiapex®) plus manual modeling and a penile traction device (PTD) in the treatment of Peyronic’s Disease (PD).

Methods: We prospectively collected all patients diagnosed with PD and treated with this combination therapy in two healthcare centres. Inclusion criteria were: age >18, informed consent given, palpable plaque, curvature >30º, adequate previous manipulation of a PTD, and important disturbance of sexual intercourse. We excluded patients with severe calcification of the plaque. We collected all demographic data, IIEF-5 and PDQ scores, comorbidities, time since onset of symptoms, and assessed the curvature with a Kelami test. We offered the patients a maximum of 4 cycles, each one consisting on 2 injections in 24-72 hours time, and followed by 6 weeks of manual modelling and a minimum of 4 hours of daily use of a PTD. We stopped the protocol if no improvement was observed after the cycle, or continued it until the curvature was <30º or the patient managed with the residual one.

Results: 63 patients were available at the time of the analysis of the data. 4 were lost to follow, so 59 were available for the analysis. Mean basal curvature was 60.44º (30-100). 59 patients received 1 cycle, 41 received 2 cycles, 15 received 3 cycles, and 4 received 4 cycles. Mean curvature at the end of the treatment was 36.05º (0-90) with a reduction of -24.39º (-40,35%). 15 patients required additional surgical treatment (7 grafting and 8 plication). The mean number of cycles was 2.07 (1-4).

Conclusion: The combination of the use of a PTD with Xiapex® is useful to reduce the number of cycles achieving similar results to those in the literature, and improving the cost-efficiency of the treatment.

Policy of full disclosure: None